Keyphrases
8-hydroxydeoxyguanosine (8-OHdG)
12%
Acute Kidney Injury
13%
Adult Patients
8%
Albumin
8%
Angiotensin-converting Enzyme
12%
Angiotensin-converting Enzyme Inhibitor (ACEi)
9%
Antihypertensive Drugs
12%
Arterial Stiffness
7%
Asymmetric Dimethylarginine
18%
Atherosclerotic Cardiovascular Disease (ASCVD)
16%
Atherosclerotic Cardiovascular Disease Risk Score
8%
Beta-blockers
8%
Blood Urea Nitrogen
10%
Bone Disorders
7%
Cardiovascular Mortality
21%
Cardiovascular Mortality Risk
25%
Carotid-femoral Pulse Wave Velocity (cfPWV)
12%
Chronic Kidney Disease
89%
Chronic Kidney Disease Patients
64%
Chronic Kidney Disease Stage
21%
COVID-19
37%
COVID-19 Patients
9%
Critically Ill COVID-19 Patients
20%
D-dimer
10%
Dialysate
12%
Dialysis
7%
Disease Progression
12%
Double-lumen Catheter
8%
Elderly Patients
12%
End-stage Renal Disease
8%
End-stage Renal Disease Patients
7%
Estimated Glomerular Filtration Rate
14%
Ethyl Acetate
12%
Fungus Comb
12%
Gene Polymorphism
12%
General Hospital
9%
Hemodialysis
52%
Hemodialysis Patients
24%
High Dose
7%
History of Hypertension
8%
Hyperkalemia
8%
Hypertension
17%
Hypertensive
9%
Hypokalemia
8%
Indonesia
26%
Indonesian
22%
Insulin Resistance
12%
Intact Parathyroid Hormone (iPTH)
14%
Interleukin-6
7%
Interleukin-6 Levels
12%
Kidney
7%
Kidney Transplantation
7%
Length of Stay
10%
Leukocytes
8%
Lupus Nephritis
12%
Macrotermes Gilvus Hagen
7%
Maintenance Hemodialysis
8%
Maintenance Hemodialysis Patients
23%
Malnutrition
7%
Mellitus Diabetes
8%
Mesenchymal Stem Cells
7%
Meta-analysis
26%
Mineral Disorders
7%
Mortality Prediction
30%
Mortality Rate
12%
Mounds
7%
Myostatin
12%
N-acetylcysteine
12%
Narrative Review
7%
Nephrology
7%
Nitrogen Levels
8%
No Significant Difference
10%
Non-associated
7%
Non-dialysis
9%
Non-dialysis Chronic Kidney Disease
23%
Non-survivors
7%
Non-tunneled Hemodialysis Catheter
12%
Parathyroid Hormone Levels
8%
Patency
7%
Polymorphism
7%
Predictive Value
8%
Proteinuria
14%
PubMed
7%
Radiological Parameters
7%
Randomized Controlled Trial
7%
Referral Hospital
19%
Regular Hemodialysis
8%
Renal Disease
7%
Retrospective Cohort Study
13%
Risk Factors
17%
Sarcopenia
19%
Serum Albumin
7%
Serum Creatinine
10%
Single nucleotide Polymorphism
9%
Surabaya
39%
Systematic Meta-analysis
26%
Termites
7%
Type 1 Diabetes Mellitus (T1DM)
25%
Ultrafiltration
9%
Universitas
8%
Medicine and Dentistry
Acetic Acid
6%
Acetic Acid Ethyl Ester
6%
Acute Kidney Injury
12%
Adipose-Derived Mesenchymal Stem Cell
6%
Angiotensin II
6%
Arterial Stiffness
6%
Beta Thalassemia
6%
Blood Urea Nitrogen
10%
Bone Density
6%
Bone Development
6%
Cardiotoxicity
6%
Cardiovascular Disease
12%
Cardiovascular Mortality
12%
Case Presentation
6%
Cation Exchange Resin
6%
Cell Function
6%
Cellular Senescence
6%
Central Venous Catheter
6%
Chondrocyte
6%
Chondrogenesis
6%
Chronic Kidney Disease
100%
Chronic Myelogenous Leukemia
6%
Cochlea
6%
Comb
6%
COVID-19
19%
Creatinine
12%
Cross Sectional Study
11%
Deep Vein Thrombosis
6%
Dengue Shock Syndrome
6%
Diabetes
6%
Diabetes Mellitus
18%
Dialysis Catheter
12%
Dialysis Fluid
6%
Digital Imaging
6%
Diseases
10%
DNA Polymorphism
12%
Doxorubicin
6%
Drug Megadose
6%
Elderly Patient
12%
Flaccid Paralysis
6%
Focal Segmental Glomerulosclerosis
6%
Glomerular Filtration Rate
6%
Heart Left Ventricle Ejection Fraction
5%
Hemodialysis
55%
Hyperkalemia
8%
Hypokalemia
8%
Hypotension
6%
Infection
6%
Insulin Resistance
12%
Iron Chelating Agent
6%
Iron Overload
6%
Isotopes of Calcium
5%
Kidney Denervation
6%
Kidney Transplantation
7%
Low Drug Dose
6%
Lupus Nephritis
12%
Lymphocyte
6%
Maturity Onset Diabetes of the Young
6%
Mesenchymal Stem Cell
16%
Meta-Analysis
14%
Mixed Infection
9%
Myostatin
6%
N(g),n(g) Dimethylarginine
12%
Neoplasm
6%
Nephropathy
7%
Nephrotic Syndrome
6%
Neurogenic Bladder
6%
Neutrophil
7%
Non-Hodgkin Lymphoma
6%
Osteoblastogenesis
6%
Osteoprotegerin
6%
Outer Hair Cell
6%
Outpatient
5%
Oxidative Stress
6%
Paralysis
6%
Parathyroidectomy
6%
Patient Referral
6%
Peritoneal Dialysis
6%
Peritoneal Fibrosis
6%
Phosphate Intake
6%
Physical Examination
6%
Polycystic Kidney Disease
6%
Prevalence
6%
Priapism
6%
Proteinuria
8%
Receptor
6%
Renal Artery Stenosis
6%
Renal Biopsy
6%
Sarcopenia
12%
Secondary Hyperparathyroidism
7%
Serositis
6%
Single Nucleotide Polymorphism
6%
Sodium Bicarbonate
6%
Somatomedin C
6%
Systematic Review
19%
Systemic Lupus Erythematosus
6%
Troponin T
6%
Tumor Necrosis Factor
6%
Vesicoureteral Reflux
6%
Vitiligo
6%
Pharmacology, Toxicology and Pharmaceutical Science
6 N,n' Dimethylarginine
12%
8 Hydroxydeoxyguanosine
6%
Acetic Acid Ethyl Ester
6%
Acetylcysteine
12%
Acute Kidney Failure
19%
Albright Syndrome
5%
Angiotensin II
6%
Angiotensin Receptor
6%
Annona muricata
6%
Antihypertensive Agent
12%
Antioxidant Capacity
6%
Bacterial Infection
6%
Beta Adrenergic Receptor Blocking Agent
7%
Beta Thalassemia
6%
C Reactive Protein
6%
Candesartan
6%
Cardiotoxicity
6%
Cardiovascular Disease
9%
Cardiovascular Mortality
12%
Cation Exchange Resin
6%
Chelating Agent
6%
Chelation Therapy
5%
Chronic Kidney Failure
96%
Cisplatin
6%
Cohort Study
13%
Comorbidity
5%
Coronary Artery Atherosclerosis
10%
Coronavirinae
12%
Creatinine
11%
Cross-Sectional Study
16%
Cystatin C
5%
D Dimer
10%
Deep Vein Thrombosis
6%
Dengue Shock Syndrome
6%
Diabetes Mellitus
16%
Dialysis Fluid
6%
Dicarbonate
6%
Disease Exacerbation
12%
Diseases
26%
Doxorubicin
6%
End Stage Renal Disease
14%
Enkephalinase Inhibitor
6%
Flaccid Paralysis
6%
Focal Glomerulosclerosis
6%
Hemodialysis
98%
Homocysteine
6%
Hyperkalemia
10%
Hypertension
12%
Hypokalemia
8%
Hypotension
6%
Infection
9%
Inflammation
7%
Inotropic Agent
6%
Insulin Resistance
12%
Interleukin 6
6%
Iron Poisoning
6%
Isoptera
6%
Isotopes of Potassium
6%
Kidney Disease
8%
Kidney Injury
7%
Macrotermes
6%
Mixed Infection
9%
Mortality Rate
10%
Mus musculus
6%
Myostatin
12%
N(g),n(g) Dimethylarginine
12%
Neoplasm
6%
Nephrotic Syndrome
6%
Non Insulin Dependent Diabetes Mellitus
6%
Nonhodgkin Lymphoma
6%
Osteodystrophy
6%
Osteoprotegerin
6%
Paralysis
6%
Parathyroid Hormone
10%
Peritoneal Fibrosis
6%
Proteinuria
8%
Randomized Controlled Trial
8%
Receptor
11%
Resistant Hypertension
6%
Sarcopenia
19%
Secondary Hyperparathyroidism
7%
Somatomedin C
6%
Tocilizumab
6%
Troponin T
6%
Ureaplasma
10%